<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="175224">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814671</url>
  </required_header>
  <id_info>
    <org_study_id>3524</org_study_id>
    <nct_id>NCT00814671</nct_id>
  </id_info>
  <brief_title>Study of Daily Rifapentine for Pulmonary Tuberculosis</brief_title>
  <official_title>A Phase 2 Randomized, Open-label Trial of Daily Rifapentine 450mg or 600mg in Place of Rifampicin 600mg for Intensive Phase Treatment of Smear-positive Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Cape Town Lung Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cape Town</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this Phase 2 study is to determine the microbiological activity and safety of
      rifapentine when given as a component of multidrug intensive phase treatment of
      smear-positive pulmonary TB.

      Funding Source- FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective phase II, open-label, single center study in which each experimental rifapentine
      regimen is evaluated using a two-stage design. Adults (HIV-negative, or HIV-positive with
      CD4 &gt; 200 cells/cu mm) suspected to have pulmonary tuberculosis who meet eligibility
      criteria will be randomized to receive one of three intensive phase regimens. Intensive
      phase regimens will consist of once daily isoniazid, pyrazinamide, and ethambutol, plus one
      of the following: rifampin 600 mg once daily OR rifapentine 450 mg once daily OR rifapentine
      600 mg once daily. Randomization will be stratified by presence/absence of cavitation on
      baseline chest radiograph. In Stage 1, 15 subjects will be randomized to each arm, following
      which there will be an enrollment pause for efficacy and safety assessment. Any rifapentine
      regimen for which fewer than 6 of 11 evaluable participants have week 8 culture conversion
      will be discarded.

      Stage 2 will randomize subjects into the remaining &quot;accepted arms&quot; with a maximum of 36
      additional subjects per arm.

      All subjects will continue TB treatment with a conventional continuation phase treatment.

      Study Site

      Study subjects will be recruited from the University of Cape Town inpatient wards and
      outpatient clinics.

      Estimated Study Duration

      It is estimated that 18 months will be required for recruitment and enrollment of study
      subjects. The estimated duration of participation for each study subject is 18 months,
      including 2 months of experimental intensive phase TB treatment, 4 months of
      non-experimental conventional continuation phase TB treatment, and an additional 12 months
      for follow-up for TB relapse.

      Study Management

      Study subjects will have study visits on days 0, 7, 14, 21, 28, 35, 42, 49, and 56 for
      sputum collection and adverse event assessment. Safety laboratory monitoring will be
      performed on days 14, 28, 42, and 56 and will consist of complete blood count, serum alanine
      aminotransferase, serum total bilirubin, and serum creatinine. Steady state pharmacokinetic
      analysis will be performed on approximately day 28. Subjects will have additional study
      visits at week 10 and at months 4, 6, 12, and 18.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Estimate the Microbiological Activity of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg Based on Proportion of Participants With Culture Conversion</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To Estimate the Frequency of Side Effects of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment</measure>
    <time_frame>10 weeks</time_frame>
    <description>discontinuation of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Microbiological Activity of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment, Based on Time to Sputum Culture Conversion</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Microbiological Activity of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment, Based on Time to Culture Growth in MGIT Liquid Media</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Describe the Pharmacokinetics of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine if Rifapentine Exposures Are Associated With Microbiological Activity</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Determine if Rifapentine Exposures Are Associated With Safety</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Compare Lowenstein Jensen and Bactec MGIT Media With Respect to Proportion of Participants With 8-week Culture Conversion and Time to Culture Conversion</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>RPT450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifapentine 450mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIF 600</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifampin 600mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 600</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifapentine 600mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine</intervention_name>
    <description>rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
    <arm_group_label>RPT450</arm_group_label>
    <arm_group_label>RPT 600</arm_group_label>
    <other_name>Priftin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifapentine</intervention_name>
    <description>rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
    <arm_group_label>RPT450</arm_group_label>
    <arm_group_label>RPT 600</arm_group_label>
    <other_name>Priftin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>rifampin 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
    <arm_group_label>RIF 600</arm_group_label>
    <other_name>Rifampacin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of
             expectorated sputum. Patients having extra-pulmonary manifestations of tuberculosis,
             in addition to smear-positive pulmonary disease, are eligible for enrollment.

          2. No prior history of tuberculosis disease or tuberculosis treatment

          3. No treatment with fluoroquinolones in the 2 months preceding initiation of study
             drugs.

          4. Age &gt; 18 years

          5. Weight ≥ 50 kg and ≤ 80 kg

          6. Karnofsky score of at least 60 (requires occasional assistance but is able to care
             for most of his/her needs; see Appendix)

          7. Signed informed consent

          8. Ability to adhere with study follow-up

          9. Women with child-bearing potential must agree to practice an adequate (barrier)
             method of birth control or to abstain from heterosexual intercourse during study
             therapy.

         10. HIV negative, or HIV-positive with CD4 &gt; 200 cells/cu mm

         11. Laboratory parameters done at, or 14 days prior to, screening (with results available
             for review by study personnel):

               -  Serum alanine aminotransferase (ALT) activity ≤ 2 times the upper limit of
                  normal

               -  Serum total bilirubin level ≤ 2 times the upper limit of normal

               -  Serum creatinine level less than or equal to the upper limit of normal

               -  Hemoglobin level of at least 7.0 g/dL

               -  Platelet count of at least 100,000/mm3

               -  Negative pregnancy test (women of childbearing potential)

        Exclusion Criteria:

          1. Pregnant or breast-feeding

          2. Known intolerance or allergy to any of the study drugs

          3. Concomitant disorders or conditions for which isoniazid (INH), rifamycins,
             pyrazinamide (PZA), or ethambutol (EMB) are contraindicated. These include severe
             hepatic damage, acute liver disease of any cause, and acute uncontrolled gouty
             arthritis.

          4. Current or planned therapy, during the intensive phase of TB therapy with
             cyclosporine or tacrolimus, or HIV antiretroviral (ARV) therapy, which have
             unacceptable interactions with rifamycins.

          5. Any medical or psychosocial condition, which, in the view of the study investigator,
             makes study participation inadvisable.

          6. Pulmonary silicosis

          7. Central nervous system TB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Dorman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universiy of Cape Town Lung Institute</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7937</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <results_reference>
    <citation>Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med. 2006 Jul 1;174(1):94-101. Epub 2006 Mar 30.</citation>
    <PMID>16574936</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenthal IM, Williams K, Tyagi S, Vernon AA, Peloquin CA, Bishai WR, Grosset JH, Nuermberger EL. Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med. 2005 Dec 1;172(11):1457-62. Epub 2005 Sep 1.</citation>
    <PMID>16141439</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 3, 2016</lastchanged_date>
  <firstreceived_date>December 24, 2008</firstreceived_date>
  <firstreceived_results_date>August 3, 2016</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Susan E. Dorman</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>192 individuals assessed for eligibility, 39 excluded, 153 randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>RPT450</title>
          <description>Rifapentine 450mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>RIF 600</title>
          <description>Rifampin 600mg daily
Rifampin: rifampin 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>RPT 600</title>
          <description>Rifapentine 600mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RPT450</title>
          <description>Rifapentine 450mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>RIF 600</title>
          <description>Rifampin 600mg daily
Rifampin: rifampin 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>RPT 600</title>
          <description>Rifapentine 600mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29" lower_limit="23" upper_limit="39"/>
                    <measurement group_id="B2" value="30" lower_limit="25" upper_limit="36"/>
                    <measurement group_id="B3" value="29" lower_limit="24" upper_limit="38"/>
                    <measurement group_id="B4" value="29" lower_limit="24" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Estimate the Microbiological Activity of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg Based on Proportion of Participants With Culture Conversion</title>
        <time_frame>8 weeks</time_frame>
        <population>per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>RPT450</title>
            <description>Rifapentine 450mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>RIF 600</title>
            <description>Rifampin 600mg daily
Rifampin: rifampin 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>RPT 600</title>
            <description>Rifapentine 600mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Estimate the Microbiological Activity of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg Based on Proportion of Participants With Culture Conversion</title>
          <population>per protocol</population>
          <units>percentage of participants w/LJ cx con</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>To Estimate the Frequency of Side Effects of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment</title>
        <description>discontinuation of treatment</description>
        <time_frame>10 weeks</time_frame>
        <population>safety analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>RPT450</title>
            <description>Rifapentine 450mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>RIF 600</title>
            <description>Rifampin 600mg daily
Rifampin: rifampin 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>RPT 600</title>
            <description>Rifapentine 600mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>To Estimate the Frequency of Side Effects of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment</title>
          <description>discontinuation of treatment</description>
          <population>safety analysis population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Microbiological Activity of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment, Based on Time to Sputum Culture Conversion</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate the Microbiological Activity of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment, Based on Time to Culture Growth in MGIT Liquid Media</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Describe the Pharmacokinetics of Rifapentine Administered at Once Daily Doses of 450 mg and 600 mg in the Context of Multidrug Intensive Phase TB Treatment</title>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine if Rifapentine Exposures Are Associated With Microbiological Activity</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Determine if Rifapentine Exposures Are Associated With Safety</title>
        <time_frame>10 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Compare Lowenstein Jensen and Bactec MGIT Media With Respect to Proportion of Participants With 8-week Culture Conversion and Time to Culture Conversion</title>
        <time_frame>8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>RPT450</title>
          <description>Rifapentine 450mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>RIF 600</title>
          <description>Rifampin 600mg daily
Rifampin: rifampin 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>RPT 600</title>
          <description>Rifapentine 600mg daily
Rifapentine: rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
Rifapentine: rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>hospitalization for lower respiratory tract infection</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>hospitalization for psychosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Susan Dorman</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-955-1755</phone>
      <email>dsusan1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
